Investigating how mutations in a specific gene affect kidney development

Who could benefit from this research

What this research studies

This research focuses on understanding the genetic and molecular mechanisms that regulate kidney development, particularly how mutations in the Wilms tumor 1 (Wt1) gene influence interactions between different cell types in the developing kidney. The project involves detailed training and mentorship for the investigator, who will employ advanced techniques in bioinformatics and in-vitro studies to explore how Wt1 mutations affect nephron progenitor cells and their communication with surrounding stromal cells. By examining these cellular interactions, the research aims to uncover the underlying processes that contribute to kidney formation and potential abnormalities.

Why it matters

Where this research is happening

• Ut Southwestern Medical Center
  Dallas, United States Active

Researchers

• Principal investigator: Drake, Keri Anne — Ut Southwestern Medical Center
• Study coordinator: Drake, Keri Anne

Related research

Other NIH-funded projects on the same topics.

• Fasting-mimicking diet and cancer stem cells in Wilms tumor

  Aiming to see if a fasting-mimicking diet can boost cancer-killing treatment while protecting healthy cells in children with Wilms tumor.

  NIH research Children's Hospital of Los Angeles · Los Angeles, United States · NIH-11434150

• Investigating the role of WT1 in a specific type of kidney cancer in children

  This study is looking at how certain gene changes in kids with Wilms tumor, a type of kidney cancer, might affect how the cancer grows and responds to treatment, with the goal of finding better ways to help those who are at higher risk.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11003706

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Personalized B7-H3 CAR T cells combined with PRAME antigen-specific T cells for relapsed embryonal tumors

  This trial tests a combined personalized B7-H3 CAR T cell and PRAME-specific T cell infusion after lymphodepleting chemotherapy in children and young adults with relapsed or refractory embryonal tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia and 1 other locations · NCT07172958

• GPC3-targeted CAR T cells armored with IL-15 and IL-21 for pediatric non‑CNS solid tumors

  This treatment will try personalized CAR T cells that target GPC3 and are engineered to make IL‑15 and IL‑21 in children and young adults with relapsed or refractory non‑CNS solid tumors that express GPC3.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT07148050

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.